These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21556033)

  • 1. Parkinson disease: PD biomarkers-use of α-synuclein reaches new levels.
    Montine TJ
    Nat Rev Neurol; 2011 May; 7(6):308-9. PubMed ID: 21556033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.
    Kruse N; Schlossmacher MG; Schulz-Schaeffer WJ; Vanmechelen E; Vanderstichele H; El-Agnaf OM; Mollenhauer B
    PLoS One; 2016; 11(4):e0153564. PubMed ID: 27116005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.
    del Campo M; Mollenhauer B; Bertolotto A; Engelborghs S; Hampel H; Simonsen AH; Kapaki E; Kruse N; Le Bastard N; Lehmann S; Molinuevo JL; Parnetti L; Perret-Liaudet A; Sáez-Valero J; Saka E; Urbani A; Vanmechelen E; Verbeek M; Visser PJ; Teunissen C
    Biomark Med; 2012 Aug; 6(4):419-30. PubMed ID: 22917144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylated α-synuclein as a potential biomarker for Parkinson's disease and related disorders.
    Foulds P; Mann DM; Allsop D
    Expert Rev Mol Diagn; 2012 Mar; 12(2):115-7. PubMed ID: 22369370
    [No Abstract]   [Full Text] [Related]  

  • 7. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for neurodegenerative diseases.
    Hansson O
    Nat Med; 2021 Jun; 27(6):954-963. PubMed ID: 34083813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
    Seino Y; Nakamura T; Kawarabayashi T; Hirohata M; Narita S; Wakasaya Y; Kaito K; Ueda T; Harigaya Y; Shoji M
    J Alzheimers Dis; 2019; 68(1):395-404. PubMed ID: 30814356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
    Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM
    Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF α-synuclein, tau, and amyloid β in Parkinson's disease.
    Shi M; Zhang J
    Lancet Neurol; 2011 Aug; 10(8):681; author's reply 681-3. PubMed ID: 21777821
    [No Abstract]   [Full Text] [Related]  

  • 12. Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.
    Mattsson-Carlgren N; Palmqvist S; Blennow K; Hansson O
    Nat Commun; 2020 Dec; 11(1):6252. PubMed ID: 33288742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
    Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
    Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
    Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
    Hannula MJ; Myöhänen TT; Tenorio-Laranga J; Männistö PT; Garcia-Horsman JA
    Neuroscience; 2013 Jul; 242():140-50. PubMed ID: 23562579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
    Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of proteins in neurodegenerative disease].
    Szwed A; Miłowska K
    Postepy Hig Med Dosw (Online); 2012 Apr; 66():187-95. PubMed ID: 22706103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 α-synuclein antibody.
    Maetzler W; Pilotto A; Apel A; Deuschle C; Kuebart G; Heinzel S; Liepelt-Scarfone I; Schulte C; Reusch D; Schleicher E; Rothfuss O; Schneider A; Dodel R; Gasser T; Berg D
    Acta Neuropathol; 2014 Dec; 128(6):893-5. PubMed ID: 25376537
    [No Abstract]   [Full Text] [Related]  

  • 20. Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels.
    Ibanez L; Dube U; Saef B; Budde J; Black K; Medvedeva A; Del-Aguila JL; Davis AA; Perlmutter JS; Harari O; Benitez BA; Cruchaga C
    BMC Neurol; 2017 Nov; 17(1):198. PubMed ID: 29141588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.